Yesterday, Nov. 10, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $354.40 to $12,639,826.44.

Highlighted Stocks Traded by Insiders:

Acadia Healthcare (ACHC) - FREE Research Report

Goldberg Randall P, who is 10% Owner at Acadia Healthcare, sold 2,824 shares at $74.01 on Nov. 10, 2015. Following this transaction, the 10% Owner owned 8,090 shares meaning that the stake was reduced by 25.88% with the 2,824-share transaction.

Carpenter Danny E, who is 10% Owner at Acadia Healthcare, sold 15,000 shares at $74.02 on Nov. 10, 2015. Following this transaction, the 10% Owner owned 48,384 shares meaning that the stake was reduced by 23.67% with the 15,000-share transaction.

The shares most recently traded at $69.77, down $4.25, or 6.09% since the insider transaction. Historical insider transactions for Acadia Healthcare go as follows:

  • 4-Week # shares sold: 157,539
  • 12-Week # shares sold: 157,539
  • 24-Week # shares sold: 160,028

The average volume for Acadia Healthcare has been 874,200 shares per day over the past 30 days. Acadia Healthcare has a market cap of $5.1 billion and is part of the health care sector and health services industry. Shares are up 15.91% year-to-date as of the close of trading on Tuesday.

Acadia Healthcare Company, Inc. The company has a P/E ratio of 46.9. Currently, there are 10 analysts who rate Acadia Healthcare a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACHC - FREE

TheStreet Quant Ratings rates Acadia Healthcare as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, compelling growth in net income and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Acadia Healthcare Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Virtusa (VRTU) - FREE Research Report

Davoli Robert E, who is Director at Virtusa, sold 5,979 shares at $52.37 on Nov. 10, 2015. Following this transaction, the Director owned 6,864 shares meaning that the stake was reduced by 46.55% with the 5,979-share transaction.

The shares most recently traded at $51.91, down $0.46, or 0.89% since the insider transaction. Historical insider transactions for Virtusa go as follows:

  • 4-Week # shares sold: 2,778
  • 12-Week # shares sold: 2,778
  • 24-Week # shares sold: 23,953

The average volume for Virtusa has been 200,200 shares per day over the past 30 days. Virtusa has a market cap of $1.6 billion and is part of the technology sector and computer software & services industry. Shares are up 25.56% year-to-date as of the close of trading on Tuesday.

Virtusa Corporation operates as an information technology (IT) services company. The company has a P/E ratio of 35.0. Currently, there are 4 analysts who rate Virtusa a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRTU - FREE

TheStreet Quant Ratings rates Virtusa as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, solid stock price performance, expanding profit margins and increase in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Virtusa Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Steris (STE) - FREE Research Report

Mcmullen Kevin M, who is Director at Steris, sold 8,000 shares at $73.73 on Nov. 10, 2015. Following this transaction, the Director owned 26,338 shares meaning that the stake was reduced by 23.3% with the 8,000-share transaction.

Bardwell Kathleen, who is Sr.V. P. & C.C.O. at Steris, sold 2,496 shares at $73.85 on Nov. 10, 2015. Following this transaction, the Sr.V. P. & C.C.O. owned 13,235 shares meaning that the stake was reduced by 15.87% with the 2,496-share transaction.

The shares most recently traded at $75.51, up $1.66, or 2.19% since the insider transaction. Historical insider transactions for Steris go as follows:

  • 4-Week # shares sold: 8,151
  • 12-Week # shares sold: 18,151
  • 24-Week # shares sold: 29,977

The average volume for Steris has been 1.0 million shares per day over the past 30 days. Steris has a market cap of $4.5 billion and is part of the health care sector and health services industry. Shares are up 17.67% year-to-date as of the close of trading on Tuesday.

STERIS Corporation develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and procedural support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The stock currently has a dividend yield of 1.34%. The company has a P/E ratio of 33.9. Currently, there are 2 analysts who rate Steris a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STE - FREE

TheStreet Quant Ratings rates Steris as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Steris Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.